Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720

This publication has 24 references indexed in Scilit:

• A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers
  Vaccine, 2001
• Efficacy of Recombinant Circumsporozoite Protein Vaccine Regimens against ExperimentalPlasmodium falciparumMalaria
  The Journal of Infectious Diseases, 2001
• Synthetic Malaria Peptide Vaccine Elicits High Levels of Antibodies in Vaccinees of Defined HLA Genotypes
  The Journal of Infectious Diseases, 2000
• Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers
  Vaccine, 2000
• Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720
  Vaccine, 1997
• Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes.
  The Journal of Experimental Medicine, 1994
• Cytotoxic CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein
  International Immunology, 1991
• Conserved Repetitive Epitope Recognized by CD4 ⁺ Clones From a Malaria-Immunized Volunteer
  Science, 1989
• The Nucleocapsid of Hepatitis B Virus Is Both a T-Cell-Independent and a T-Cell-Dependent Antigen
  Science, 1986
• Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes.
  The Journal of Experimental Medicine, 1983